Exelixis
EXEL
#1855
Rank
S$14.16 B
Marketcap
S$52.61
Share price
-2.18%
Change (1 day)
16.00%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): S$3.09

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$3.03. In 2023 the company made an earnings per share (EPS) of S$0.83 an increase over its 2022 EPS that were of S$0.73.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$3.09
2023S$0.8314.61%
2022S$0.73-22.97%
2021S$0.94100%
2020S$0.47-65.09%
2019S$1.35-53.91%
2018S$2.93333.96%
2017S$0.67-260.61%
2016S-$0.42-58.75%
2015S-$1.02-42.45%
2014S-$1.775.3%
2013S-$1.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
S$13.28 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$2.19-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$16.58 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$4.71 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$9.66 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$3.78 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$4.57 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
S-$4.67-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.07-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA